BOSTON SCIENTIFIC CORP is expected to release its Q3 2026 10-Q filing on October 20, 2026, before market open. Last quarter: Boston Scientific posted 7.5% revenue growth and a 70.7% gross margin in Q2 FY2026, propelled by its Cardiovascular segment, while aggressive capital deployment and a major pending acquisition highlight both opportunity and risk.
EPS Estimate
$0.81
Revenue Estimate
$5.31B
Analyst consensus from Finnhub and Financial Modeling Prep. Actual results posted within minutes of the SEC filing on the BSX page.
Drawn from management commentary in the Q2 2026 10-Q:
Gross margin rose to 70.7% from 67.7% a year ago, driven by increased sales of higher-margin products, a benefit from the recovery of previously incurred tariffs, and a decrease in inventory charges, only partially offset by unfavorable foreign currency effects.
Reported net sales growth in the Cardiovascular segment was led by the coronary therapies franchise (notably the AGENT Drug-Coated Balloon) and the Electrophysiology business (FARAPULSE PFA System), though the latter experienced increased competition and a deceleration of certain WATCHMAN procedures.
The planned acquisition of Penumbra, valued at approximately $14.5 billion, is expected to close in the second half of 2026, subject to FTC review and other closing conditions. The deal will be funded through $11 billion in cash and newly issued debt, plus shares, and would be integrated into the Cardiovascular division.
Revenue
$5.44B
+7.53% YoY
EPS (Diluted)
$0.61
+15.09% YoY
Gross Margin
70.7%
+3.1 pts YoY
Operating Income
$1.18B
+43.83% YoY
Add BSX to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.